24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
AFALIEVA 40MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | AFALIEVA 40MG |
|---|---|
| Composition | Afatinib Tablets IP 40mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (28 tab) |
| Country of Origin | India |
AFALIEVA 40MG (Afatinib Tablets IP 40mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
AFALIEVA 40 MG (Afatinib Tablets IP 40 mg) is a prescription targeted anticancer medication containing Afatinib 40 mg, a highly effective tyrosine kinase inhibitor (TKI) used in the treatment of specific types of Non-Small Cell Lung Cancer (NSCLC) associated with Epidermal Growth Factor Receptor (EGFR) mutations. Afatinib is designed to target and block abnormal proteins that drive cancer cell growth, multiplication, and spread throughout the body.
Lung cancer is among the most frequently diagnosed cancers worldwide, and advances in molecular diagnostics have made it possible to identify genetic mutations that can be specifically targeted with precision medicines. Patients whose tumors carry EGFR mutations often benefit from targeted therapies such as Afatinib, which are developed to attack cancer cells more selectively than traditional chemotherapy.
AFALIEVA 40 MG works by irreversibly inhibiting members of the ErbB receptor family, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). These receptors are involved in signaling pathways that regulate cell growth and survival. When mutated, they can cause uncontrolled cancer cell proliferation. By blocking these signals, Afatinib helps slow tumor growth, reduce disease progression, and improve clinical outcomes.
Unlike conventional chemotherapy, which affects both healthy and cancerous cells, targeted therapies focus on specific cancer-driving mechanisms. This approach allows for more personalized treatment and has become a cornerstone of modern oncology.
AFALIEVA 40 MG is commonly prescribed for:
Before treatment begins, patients generally undergo molecular testing to confirm the presence of EGFR mutations and determine eligibility for Afatinib therapy.
Manufactured under strict pharmaceutical quality standards, AFALIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Afatinib treatment usually require regular monitoring through clinical assessments, blood tests, liver function evaluations, and treatment response reviews to ensure optimal outcomes.
Due to its proven efficacy and targeted mechanism of action, AFALIEVA 40 MG is widely recognized as an important treatment option in modern lung cancer management.
AFALIEVA 40 MG (Afatinib Tablets IP 40 mg) is primarily used in the treatment and management of EGFR mutation-positive lung cancer.
The medicine is widely prescribed for patients diagnosed with EGFR-positive NSCLC.
Afatinib helps manage advanced-stage lung cancer that cannot be effectively treated with surgery alone.
The medicine may be used when cancer has spread beyond the lungs to other parts of the body.
Doctors may prescribe Afatinib for patients with locally advanced disease requiring targeted therapy.
The medicine may help manage lung cancer that returns after previous treatment.
In selected cases, Afatinib may be used as part of treatment strategies for squamous cell lung cancer.
The medicine supports personalized treatment approaches based on genetic testing results.
Afatinib helps delay disease progression and maintain treatment response.
Afatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
AFALIEVA works by:
This targeted mechanism helps control cancer growth and supports long-term disease management.
Like all medicines, AFALIEVA 40 MG may cause side effects in some patients. The severity and frequency of side effects can vary depending on individual factors and treatment duration.
Diarrhea is one of the most commonly reported side effects and may require medical management.
Patients may develop acne-like skin rashes during treatment.
Skin dryness, irritation, and sensitivity may occur.
Painful ulcers or inflammation inside the mouth may develop.
Changes around fingernails and toenails may occur.
Reduced appetite may affect nutritional intake.
Weakness and tiredness are commonly experienced.
Some patients may experience mild to moderate nausea.
Weight reduction may occur during prolonged treatment.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of AFALIEVA 40 MG (Afatinib Tablets IP 40 mg) should always be determined by a qualified oncologist.
The prescribed dosage depends on the cancer diagnosis and mutation profile.
Doctors may adjust dosage according to treatment effectiveness and patient tolerance.
Dose modifications may be required if significant side effects develop.
Liver and kidney health may influence treatment planning.
Individual patient factors contribute to dosage decisions.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant or breastfeeding women should only use this medicine if specifically recommended by a healthcare professional.
It is primarily used for the treatment of EGFR mutation-positive Non-Small Cell Lung Cancer (NSCLC).
Afatinib is a targeted anticancer medicine that blocks EGFR and related receptors involved in cancer cell growth and survival.
No. It is a targeted therapy that works differently from traditional chemotherapy medicines.
Genetic testing helps determine whether the cancer contains EGFR mutations that are likely to respond to Afatinib therapy.
Yes. Skin rash, dry skin, and nail changes are among the commonly reported side effects.
Yes. Diarrhea is one of the most common side effects and should be managed under medical supervision.
Yes. Routine blood tests, liver assessments, and clinical evaluations are important throughout treatment.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and targeted cancer treatment.